πŸ‡ΊπŸ‡Έ FDA
Patent

US 11427823

Targeted compositions

granted A61KA61K47/549A61K47/554

Quick answer

US patent 11427823 (Targeted compositions) held by ARBUTUS BIOPHARMA CORPORATION expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARBUTUS BIOPHARMA CORPORATION
Grant date
Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K47/549, A61K47/554, A61P, A61P1/16